Endocarditis
Chief's Pearl
This week we will review the diagnostic criteria for INFECTIOUS ENDOCARDITIS. Now that children with congenital heart disease have much improved survival rates, and with the overall decrease in rheumatic valvular heart disease in developed countries, CHD now constitutes the predominant underlying condition for IE in children over 2 years of age. In about 8-10% of cases, IE develops without structural heart disease or other identifiable risk factors, i.e. indwelling catheters, and usually involves infection of the aortic or mitral valve due to Staph aureus bacteremia. In terms of congenital heart disease, any lesion associated with TURBULENT flow, with or without shunting, can be a substrate for IE, i.e. VSD, PDA, aortic valve anomaly, TOF.
The diagnosis of IE is based on the DUKE
CRITERIA:
Major Criteria
Minor Criteria
1)
Predisposition: predisposing heart condition or IV drug use
2) Fever:
temp >/= 38.0 C
3) Vascular
phenomena: major arterial emboli, septic pulmonary infarcts, mycotic aneurysm,
intracranial hemorrhage, conjunctival hemorrhages, and Janeway lesions
4)
Immunologic phenomena: glomerulonephritis, Osler nodes, Roth's spots, and
rheumatoid factor
5)
Microbiological evidence: positive blood culture but does not meet a
major criterion as noted above or serological evidence of active infection with
organism consistent with IE
6) Echocardiographic findings: consistent with IE but do not meet a major criterion as noted above
Definite IE:
Clinical criteria:
2 major criteria,
or
1 major criterion and 3 minor criteria,
or
5 minor criteria
Pathological criteria:
> Micro-organisms: demonstrated by culture
or histology in a vegetation, a vegetation that has embolized, or an
intracardiac abscess, or
> Pathological lesions: vegetation or intracardiac abscess present, confirmed by histology showing active endocarditis
Possible IE:
Findings consistent with IE that fall short of
"definite" but not "rejected"
Rejected:
You can find the entire article titled, "Unique Features of Infective Endocarditis in Childhood" in Pediatrics, May 2002, or from the American Heart Association. Because of all of the CHD we see here, this is something we need to keep in mind. We hope this helps.
===
Of the following, the finding that is MOST indicative of bacterial endocarditis in an adolescent who has mitral valve prolapse is
Documentation of bacteremia caused by a typical pathogen such as one
of the viridans streptococcal organisms is a conclusive indication of
endocarditis associated with mitral valve prolapse in an adolescent. (Answer A)
In addition to the American Heart Association-accepted criterion of
mitral
valve regurgitation,
echocardiographic evidence of
mitral
valve redundancy and thickening is a possible risk factor for
endocarditis. Increased thickening of the valve may represent early
vegetation formation in the presence of bacterial endocarditis, but in
isolation, it does not constitute definitive evidence of endocarditis.
Fever and splenomegaly also occur in patients who have bacterial
endocarditis; splenomegaly is more common in patients who have had fever and
bacteremia for weeks (subacute bacterial endocarditis). However, these findings
also are typical manifestations of
infectious mononucleosis, a diagnosis that is much more common in
adolescence than infectious endocarditis.
Microscopic hematuria is a well-described finding in many patients who
have subacute or long-standing endocarditis. It
represents a form of
glomerulonephritis from immune
complex deposition and is associated with low circulating complement levels.
However, there are other more common causes of microscopic hematuria in an
adolescent female, such as urinary tract infection.
Many patients who have mitral valve prolapse also have mitral valve
regurgitation. It is believed that these patients are at a significantly
higher risk to develop bacterial endocarditis than mitral prolapse patients who
do not have valvular regurgitation, but the occurrence of
fever in such patients is not diagnostic
of endocarditis.
Pericarditis, Bacterial
References:
Bayer AS, Bolger AF, Taubert KA, et al. American Heart Association. AHA
scientific statement. Diagnosis and management of infective endocarditis and its
complications. 1998. Available at:
Bonow RO, Carabello B, de Leon AC Jr, et al. ACC/AHA guidelines for the
management of patients with valvular heart disease: a report of the American
College of Cardiology/American Heart Association Task Force on Practice
Guidelines (Committee on Management of Patients With Valvular Heart Disease). J
Am Coll Cardiol. 1998;32:1486-1588
Brook MM. Pediatric bacterial endocarditis. Treatment and prophylaxis. Pediatr
Clin North Am. 1999;46:275-287